Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.

Division

North Florida

Hospital

Ocala Regional Medical Center

Document Type

Case Report

Publication Date

6-1-2021

Keywords

arrhythmia, atrial fibrillation, ekg, evolocumab, hyperlipidemia, pcsk-9 inhibitor

Disciplines

Cardiovascular Diseases | Internal Medicine

Abstract

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.

Publisher or Conference

Cureus

Link to Full Text

Share

COinS